Lazard Asset Management
MACK

Lazard Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Lazard Asset Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,830
Closed -$41K – 2481
2024
Q1 		$41K Hold
2,830
– – ﹤0.01% 1761
2023
Q4 		$37K Sell
2,830
-293
-9% -$3.7K ﹤0.01% 1975
2023
Q3 		$38K Hold
3,123
– – ﹤0.01% 1935
2023
Q2 		$38K Sell
3,123
-1,828
-37% -$22.9K ﹤0.01% 1920
2023
Q1 		$60K Buy
+4,951
New +$58.2K ﹤0.01% 1739
2016
Q3 		– Sell
-118
Closed -$5K – 1083
2016
Q2 		$5K Sell
118
-10,597
-99% -$577K ﹤0.01% 1000
2016
Q1 		$705K Buy
10,715
+10,362
+2,935% +$541K ﹤0.01% 698
2015
Q4 		$21K Buy
+353
New +$24.8K ﹤0.01% 974
2015
Q3 		– Sell
-881
Closed -$85K – 1199
2015
Q2 		$85K Buy
+881
New +$83.8K ﹤0.01% 930

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Lazard Asset Management's MACK Position: Q2 2024 in Review

Lazard Asset Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 2,830 shares — an estimated $41K sold.

Lazard Asset Management first reported a position in MACK in Q2 2015 and held it in 9 quarters. The position peaked at $705K in Q1 2016. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • Lazard Asset Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Lazard Asset Management sold 2,830 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $41K.
  • Lazard Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2015 and held it in 9 quarters.
  • Lazard Asset Management's Merrimack Pharmaceuticals, Inc. position peaked at $705K in Q1 2016.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Lazard Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.